Key statistics
As of last trade Axsome Therapeutics Inc (19X:MUN) traded at 135.80, -15.89% below its 52-week high of 161.45, set on Jan 22, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 137.05 |
|---|---|
| High | 137.05 |
| Low | 135.80 |
| Bid | 139.65 |
| Offer | 140.60 |
| Previous close | 137.50 |
| Average volume | 147.14 |
|---|---|
| Shares outstanding | 51.15m |
| Free float | 42.90m |
| P/E (TTM) | -- |
| Market cap | 8.38bn USD |
| EPS (TTM) | -3.69 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 08:05 GMT.
More ▼
Announcements
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
- Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
- Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
- Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
More ▼
